FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313888043> ?p ?o ?g. }

• W4313888043 abstract "Abstract Background/aims Nonobese metabolic dysfunction-associated fatty liver disease (MAFLD) is paradoxically associated with improved metabolic and pathological features at diagnosis but similar cardiovascular diseases (CVD) prognosis to obese MAFLD. We aimed to utilize the metabolomics to identify the potential metabolite profiles accounting for this phenomenon. Methods This prospective multicenter cross-sectional study was conducted in China enrolling derivation and validation cohorts. Liquid chromatography coupled with mass spectrometry and gas chromatography-mass spectrometry were applied to perform a metabolomics measurement. Results The study involved 120 MAFLD patients and 60 non-MAFLD controls in the derivation cohort. Controls were divided into two groups according to the presence of carotid atherosclerosis (CAS). The MAFLD group was further divided into nonobese MAFLD with/without CAS groups and obese MAFLD with/without CAS groups. Fifty-six metabolites were statistically significant for discriminating the six groups. Among the top 10 metabolites related to CAS in nonobese MAFLD, only phosphatidylethanolamine (PE 20:2/16:0), phosphatidylglycerol (PG 18:0/20:4) and de novo lipogenesis (16:0/18:2n-6) achieved significant areas under the ROC curve (AUCs, 0.67, p = 0.03; 0.79, p = 0.02; 0.63, p = 0.03, respectively). The combination of these three metabolites and liver stiffness achieved a significantly higher AUC (0.92, p < 0.01). In obese MAFLD patients, cystine was found to be significant with an AUC of 0.69 ( p = 0.015), followed by sphingomyelin (SM 16:1/18:1) (0.71, p = 0.004) and de novo lipogenesis (16:0/18:2n-6) (0.73, p = 0.004). The combination of these three metabolites, liver fat content and age attained a significantly higher AUC of 0.91 ( p < 0.001). The AUCs of these metabolites remained highly significant in the independent validation cohorts involving 200 MAFLD patients and 90 controls. Conclusions Diagnostic models combining different metabolites according to BMI categories could raise the accuracy of identifying subclinical CAS. Trial registration The study protocol was approved by the local ethics committee and all the participants have provided written informed consent (Approval number: [2014] No. 112, registered at the Chinese Clinical Trial Registry, ChiCTR-ChiCTR2000034197) Graphical Abstract" @default.
• W4313888043 created "2023-01-10" @default.
• W4313888043 creator A5007869048 @default.
• W4313888043 creator A5014479614 @default.
• W4313888043 creator A5018344352 @default.
• W4313888043 creator A5019021403 @default.
• W4313888043 creator A5023997325 @default.
• W4313888043 creator A5046597133 @default.
• W4313888043 creator A5056151772 @default.
• W4313888043 date "2023-01-09" @default.
• W4313888043 modified "2023-10-16" @default.
• W4313888043 title "Metabolomics to identify fingerprints of carotid atherosclerosis in nonobese metabolic dysfunction-associated fatty liver disease" @default.
• W4313888043 cites W1570688778 @default.
• W4313888043 cites W2002349652 @default.
• W4313888043 cites W2035598079 @default.
• W4313888043 cites W2066125186 @default.
• W4313888043 cites W2080295355 @default.
• W4313888043 cites W2092706951 @default.
• W4313888043 cites W2139351004 @default.
• W4313888043 cites W2144636739 @default.
• W4313888043 cites W2196906371 @default.
• W4313888043 cites W2309231815 @default.
• W4313888043 cites W2321394973 @default.
• W4313888043 cites W2398595650 @default.
• W4313888043 cites W2399261310 @default.
• W4313888043 cites W2517706500 @default.
• W4313888043 cites W2530466621 @default.
• W4313888043 cites W2553298154 @default.
• W4313888043 cites W2599094376 @default.
• W4313888043 cites W2603152534 @default.
• W4313888043 cites W2611881317 @default.
• W4313888043 cites W2618741738 @default.
• W4313888043 cites W2740032199 @default.
• W4313888043 cites W2748864304 @default.
• W4313888043 cites W2764061735 @default.
• W4313888043 cites W2767077321 @default.
• W4313888043 cites W2768802082 @default.
• W4313888043 cites W2803425795 @default.
• W4313888043 cites W2807614554 @default.
• W4313888043 cites W2900934742 @default.
• W4313888043 cites W2934773189 @default.
• W4313888043 cites W2944625943 @default.
• W4313888043 cites W2947682777 @default.
• W4313888043 cites W2949366556 @default.
• W4313888043 cites W2985481640 @default.
• W4313888043 cites W2986141565 @default.
• W4313888043 cites W3000235757 @default.
• W4313888043 cites W3006663297 @default.
• W4313888043 cites W3015579983 @default.
• W4313888043 cites W3091243730 @default.
• W4313888043 cites W3091471007 @default.
• W4313888043 cites W3096887326 @default.
• W4313888043 cites W3099919713 @default.
• W4313888043 cites W3109763776 @default.
• W4313888043 cites W3111217257 @default.
• W4313888043 cites W3118884590 @default.
• W4313888043 cites W3217254653 @default.
• W4313888043 cites W4200279068 @default.
• W4313888043 cites W4214874395 @default.
• W4313888043 cites W4220729842 @default.
• W4313888043 cites W4221052940 @default.
• W4313888043 cites W4280552835 @default.
• W4313888043 doi "https://doi.org/10.1186/s12967-022-03760-6" @default.
• W4313888043 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36624524" @default.
• W4313888043 hasPublicationYear "2023" @default.
• W4313888043 type Work @default.
• W4313888043 citedByCount "2" @default.
• W4313888043 countsByYear W43138880432023 @default.
• W4313888043 crossrefType "journal-article" @default.
• W4313888043 hasAuthorship W4313888043A5007869048 @default.
• W4313888043 hasAuthorship W4313888043A5014479614 @default.
• W4313888043 hasAuthorship W4313888043A5018344352 @default.
• W4313888043 hasAuthorship W4313888043A5019021403 @default.
• W4313888043 hasAuthorship W4313888043A5023997325 @default.
• W4313888043 hasAuthorship W4313888043A5046597133 @default.
• W4313888043 hasAuthorship W4313888043A5056151772 @default.
• W4313888043 hasBestOaLocation W43138880431 @default.
• W4313888043 hasConcept C126322002 @default.
• W4313888043 hasConcept C134018914 @default.
• W4313888043 hasConcept C21565614 @default.
• W4313888043 hasConcept C2778772119 @default.
• W4313888043 hasConcept C2779134260 @default.
• W4313888043 hasConcept C60644358 @default.
• W4313888043 hasConcept C71924100 @default.
• W4313888043 hasConcept C86803240 @default.
• W4313888043 hasConcept C90924648 @default.
• W4313888043 hasConceptScore W4313888043C126322002 @default.
• W4313888043 hasConceptScore W4313888043C134018914 @default.
• W4313888043 hasConceptScore W4313888043C21565614 @default.
• W4313888043 hasConceptScore W4313888043C2778772119 @default.
• W4313888043 hasConceptScore W4313888043C2779134260 @default.
• W4313888043 hasConceptScore W4313888043C60644358 @default.
• W4313888043 hasConceptScore W4313888043C71924100 @default.
• W4313888043 hasConceptScore W4313888043C86803240 @default.
• W4313888043 hasConceptScore W4313888043C90924648 @default.
• W4313888043 hasFunder F4320321001 @default.
• W4313888043 hasFunder F4320321921 @default.
• W4313888043 hasFunder F4320335443 @default.
• W4313888043 hasIssue "1" @default.
• W4313888043 hasLocation W43138880431 @default.

• next